Kala Pharmaceuticals Total Assets 2016-2021 | KALA

Kala Pharmaceuticals total assets from 2016 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Kala Pharmaceuticals Annual Total Assets
(Millions of US $)
2020 $222
2019 $154
2018 $221
2017 $117
2016 $46
2015 $0
Kala Pharmaceuticals Quarterly Total Assets
(Millions of US $)
2021-09-30 $194
2021-06-30 $215
2021-03-31 $230
2020-12-31 $222
2020-09-30 $225
2020-06-30 $246
2020-03-31 $259
2019-12-31 $154
2019-09-30 $161
2019-06-30 $179
2019-03-31 $197
2018-12-31 $221
2018-09-30 $84
2018-06-30 $96
2018-03-31 $105
2017-12-31 $117
2017-09-30 $124
2017-06-30 $29
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2015-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.113B $0.006B
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90